A RECOMBINANT STRAIN HAVING MODIFIED SUGAR METABOLIC PATHWAY AND METHOD FOR SCREENING SUGAR ISOMERASE USING SAME

TECHNICAL FIELD

The present invention relates to a recombinant strain having a modified sugar metabolic pathway resulting from the introduction of an enzyme derived from a different strain to a strain, and a high-speed screening method for various mutants and variants which can use the same to obtain useful materials or which can produce useful materials.

BACKGROUND ART

L-arabinose isomerase (AI) (EC 5.3.1.5) is an enzyme that converts L-arabinose to L-ribulose in vivo, but converts D-galactose, structurally similar substrate to L-arabinose, into D-tagatose in vitro. Therefore, D-tagatose can be produced efficiently by using L-arabinose isomerase with high affinity and high activity for D-galactose.

D-tagatose is an isomer of D-galactose and is a natural saccharide present in fruits, milk, cheese and the like. D-tagatose has various health functional properties and sweetness very similar to sugar so that, when applied to various products, D-tagatose is used as a substitute sweetener that is healthy and tasty at the same time.

Meanwhile, directed evolution techniques have been used as an improved technique for converting the characteristics of enzymes to satisfy desired purposes such as enhancing the activity and structural stability of the enzyme or imparting an activity on a new substrate. One of the most common methods for producing mutant libraries to perform these techniques is to introduce random mutations by controlling the error rate of DNA polymerase during PCR using error-prone PCR method. The mutantsare expressed, and then the mutants with excellent activity are selected to obtain improved enzymes. Developing effective screening technology for the characteristics and purpose of desired enzymes can be a core technology of the directed evolution.

There have been attempts to construct various mutants such as random mutation methods and point mutation methods to construct an enzyme modification library. However, these methods have limitations in applying the directed evolution technology to screen for 10⁷or more mutants due to the absence of an ultra-fast screening method of modified enzymes. In other words, it is necessary to study a novel enzyme screening method that can replace the conventional methods which can not screen at high speed in order to apply the protein engineering technique of the sugar converting enzymes.

DISCLOSURE
Technical Problem

To obtain a new enzyme for rare sugar, the present inventors have focused on the construction of novel metabolic pathways and a high-speed screening method of sugar converting enzymes. In this regard, it was confirmed that a gene encoding D-tagatose-1,6-bisphosphate aldolase (TBA) and a gene encoding L-arabinose isomerase (AI) are introduced into a non-galactose-utilizing stain so that it is possible to obtain a strain having a new sugar metabolic pathway and quickly to screen novel sugar isomerase by constructing the library in which mutation is randomly introduced into genes encoding AI and by measuring the strain growth using the library, thereby completing the present invention.

Therefore, the present invention aims to provide a method for rapidly screening novel strains having the isomerization activity of interest and the sugar metabolic activity using newly-constructed sugar metabolic pathway, thereby screening the novel mutant sugar isomerase with high speed,

Technical Solution

In order to achieve the objects, the present invention provides a method of rapidly screening a mutant with the first sugar metabolic activity and the second sugar isomerization activity, the method including the steps of: 1) screening an enzyme essential for the first sugar metabolism through genomic analysis of the first sugar metabolic strain and a strain without the first sugar metabolic activity; 2) preparing a first sugar metabolic recombinant strain by introducing a gene encoding the enzyme screened in step 1) into a strain without the first sugar metabolic activity and the second sugar isomerization activity; 3) generating a second sugar isomerase mutant library by random mutagenesis; 4) introducing a gene mutant library obtained in step 3) into the first sugar metabolic recombinant strain prepared in step 2) to obtain a strain library; and 5) culturing a strain of the library obtained in step 4) in a defined medium supplemented with the second sugar as a sole carbon source and confirming the growth and growth rate of the strain, in which the first sugar and the second sugar are mutual isomers.

Further, the present invention provides a method of rapidly screening a mutant sugar isomerase with second sugar isomerization activity, the method including the steps of: 1) screening an enzyme essential for the first sugar metabolism through genomic analysis of the first sugar metabolic strain and a strain without the first sugar metabolic activity; 2) preparing a first sugar metabolic recombinant strain by introducing a gene encoding the enzyme screened in step 1) into a strain without the first sugar metabolic activity and the second sugar isomerization activity; 3) generating a second sugar isomerase mutant library by random mutagenesis; 4) introducing a gene mutant library obtained in step 3) into the first sugar metabolic recombinant strain prepared in step 2) to obtain a strain library; 5) culturing a strain of the library obtained in step 4) in a defined medium supplemented with the second sugar as a sole carbon source and screening the strain with faster growth rate; and 6) confirming a mutant enzyme introduced into the strain screened in step 5), in which the first sugar and the second sugar are mutual isomers

Further, the present invention provides a recombinant vector containing a gene encoding D-tagatose-1,6-bisphosphate aldolase and a gene encoding L-arabinose isomerase.

Further, the present invention provides a recombinant strain with D-tagatose and D-galactose metabolic activity, in which the strain is introduced with a gene encoding D-tagatose-1,6-bisphosphate aldolase and a gene encoding L-arabinose isomerase.

Further, the present invention provides a method of preparing a recombinant strain with D-tagatose and D-galactose metabolic activity, the method including: introducing a gene encoding D-tagatose-1,6-bisphosphate aldolase and a gene encoding L-arabinose isomerase into a D-galactose non-metabolic strain.

Further, the present invention provides an L-arabinose isomerase variants with the sugar isomerization activity, the enzymes being represented by one amino acid sequence selected from the group consisting of SEQ ID NO. 2 to SEQ ID NO. 4.

Advantageous Effects

The use of a high speed screening method, a recombinant vector and a strain according to the present invention not only can construct a new sugar metabolic pathway in a strain to effectively obtain D-tagatose fro D-galactose, but also can introduce randomly modified sugar isomerases and then conduct a cell growth-associated screening system, thereby rapidly screening useful sugar isomerization mutant enzyme.

DESCRIPTION OF DRAWINGS

FIG. 1 is a schematic diagram showing a novel sugar metabolic pathway introduced into a strain for constructing a cell growth-associated screening system according to the present invention.

FIG. 2 illustrates the growth curves of Escherichia coli cells in a complex medium (LB) and a defined medium (M9) in which glucose (glc) and D-galactose (gal) are added as a sole carbon source.

FIG. 3 illustrates the organization of the D-tagatose catabolic gene clusters of a microorganism with D-tagatose metabolic activity and of a microorganism without D-tagatose metabolic activity.

FIG. 4 is a schematic diagram of the expression vector of recombinant cloning of gatY gene related to D-tagatose metabolic activity.

FIG. 5 illustrates the results of SDS-PAGE analysis of protein expression by the foreign gene introduction by transfection of a gatY gene into E. coli (Lane 1: E. coli without gatY gene introduced and Lane 2: E. coli with gatY gene introduced).

FIG. 6 illustrates the growth curves of the strain to confirm D-tagatose metabolic activity E. coli with gatY gene introduced.

FIG. 7 illustrates the colonies forming of E. coli with gatY gene in defined solid medium supplemented with tagatose as a sole carbon source to confirm the strain growth.

FIG. 8 is a schematic diagram of a pET-22b(+)-ECAI recombinant cloning expression vector.

FIG. 9 shows the results of SDS-PAGE analysis of the expression of gatY gene (31 kDa) and araA gene (56 kDa) encoding L-arabinose isomerase (AI).

FIG. 10 illustrates the growth curves of E. coli recombinant strain harboring a gene encoding D-tagatose-1,6-bisphosphate aldolase (TBA) and a gene encoding L-arabinose isomerase (AI) in medium supplemented with glucose or D-galactose and confirming the cell growth.

FIG. 11 illustrates a growth curves of E. coli harboring araA random mutagenesis library on D-galactose as carbon source for screening of improved encoding L-arabinose isomerase (AI) variants.

FIG. 12 illustrates the effects of mutations on L-arabinose isomerase (AI) activity selected by cell growth-associated high-speed screening system.

MODES OF THE INVENTION

Unless otherwise defined herein, the terms have the meanings commonly used in the art to which the present invention pertains.

The present invention provides a method of rapidly screening a mutant with the first sugar metabolic activity and the second sugar isomerization activity, the method including the steps of: 1) screening an enzyme essential for the first sugar metabolism through genomic analysis of the first sugar metabolic strain and a strain without the first sugar metabolic activity; 2) preparing a first sugar metabolic recombinant strain by introducing a gene encoding the enzyme screened in step 1) into a strain without the first sugar metabolic activity and the second sugar isomerization activity; 3) generating a second sugar isomerase mutant library by random mutagenesis; 4) introducing a gene mutant library obtained in step 3) into the first sugar metabolic recombinant strain prepared in step 2) to obtain a strain library; and 5) culturing a strain of the library obtained in step 4) in a defined medium supplemented with the second sugar as a sole carbon source and confirming the growth and growth rate of the strain, in which the first sugar and the second sugar are mutual isomers.

The recombinant strain of the present invention is an expression host in which the sugar metabolic pathway is newly constructed to allow the second sugar isomerization activity and first sugar metabolic activity. The strain can isomerize the second sugar into first sugar by the newly constructed sugar metabolic pathway and can effectively metabolize the first sugar produced from the isomerization. Therefore, when the recombinant strain is cultured in a medium containing the second sugar as a sole carbon source, it can exhibit a high growth as compared with the wild type strain which does not change the sugar metabolism pathway. By the comparison of the growth rates, a strain containing an enzyme capable of effectively isomerizing the second sugar can be rapidly screened among the variants by random mutagenesis.

The first sugar and the second sugar in the isomeric relationship used in the present invention may include all conventional sugar isomers known in the art without limitation, but may preferably include a combination selected from the group consisting of a first combination in which the first sugar is tagatose and the second sugar is galactose; a second combination in which the first sugar is fructose and the second sugar is glucose; a third combination in which the first sugar is tagatose and the second sugar is fructose; a fourth combination in which the first sugar is mannose and the second sugar is glucose; a fifth combination in which the first sugar is glucose and the second sugar is galactose; and a sixth combination in which the first sugar is fructose and the second sugar is galactose.

One of ordinary skills in the art can select and use the first sugar and second sugar with the isomeric relationship suitable for constructing the sugar metabolic pathway necessary to obtain the desired mutant sugar isomerase. For example, an embodiment of the present invention discloses a method for obtaining a novel mutant isomerase capable of converting D-galactose (second sugar) into D-tagatose (first sugar). First, D-tagatose-1,6-bisphosphate aldolase (TBA), an enzyme capable of providing D-tagatose metabolic activity as the first sugar, is selected, and the gene gatY encoding the same is introduced into a strain without D-galactose metabolic activity. Then, in order to rapidly screen the mutant enzyme capable of isomerizing D-galactose, the second sugar, the L-arabinose isomerase (AI)-random mutant library is generated, and the gene library is introduced into the recombinant strain with tagatose metabolic activity with gatY gene introduced. When the recombinant strain is cultured in a medium containing D-galactose as the sole carbon source, it is possible to grow only the strain capable of effectively converting D-galactose to produce D-tagatose. Thus, the method of comparing strain growths may be used to rapidly screen a novel D-galactose mutant isomerase with D-galactose converting activity, in other words, a strain with L-arabinose (AI) mutant isomerase.

When conducting step 1) of screening an enzyme essential for the first sugar metabolism through genomic analysis of the first sugar metabolic strain and a strain without the first sugar metabolic activity, a person skilled in the art may use methods known in the art to carry out, without limitation, the comparison and genomic analysis of strains required to derive essential enzymes associated with metabolic activity of the desired first sugar.

When a gene encoding an enzyme essential for the first sugar metabolism such as D-tagatose-1,6-bisphosphate aldolase (TBA) is introduced as in the above steps 1) and 2), the sugar metabolic pathway is newly constructed in the strain without D-tagatose metabolic activity, which does not have strain growth in a conventional medium containing D-tagatose as a sole carbon source, and thus the strain growth can occur in the medium supplemented with D-tagatose.

Step 3) is a process of generating random mutations in the second sugar isomerase, for example, a gene encoding L-arabinose isomerase (AI) to obtain a gene mutant library. The term “random mutagenesis” means that any mutation is generated in a normal sequence as a template by an error-prone PCR, which is mutagenesis PCR. The term “gene mutant library” refers to a group or set of mutant genes obtained through random mutation.

Step 4) refers to a process of introducing a gene mutant library into the first sugar metabolic recombinant strain in step 2), for example, D-tagatose metabolic strain to obtain a strain library and means that D-tagatose metabolic strain additionally expresses mutant genes, thereby obtaining strain library in which the sugar metabolic pathway is newly constructed.

Each kind of individual mutant genes of the gene mutant library can be introduced into the D-tagatose metabolic strain of step 2). A strain library in which various mutant genes are newly introduced can be obtained through this process.

Step 5) is a process of culturing the strain of the strain library in a medium containing the second sugar as a sole carbon source to confirm the growth of the cell, which can observe the cell growth, thereby rapidly confirming whether the corresponding strain obtains the second sugar-converting ability. In particular, a strain showing excellent growth of the cell can be selected as a strain obtaining the second sugar-converting ability. The mutant gene of gene mutant library in step 3), which is introduced into the corresponding strain, is confirmed to derive a mutant with the second sugar isomerization activity imparting the second sugar-converting ability and the mutant enzyme introduced into the mutant.

Therefore, the present invention provides a method of rapidly screening a mutant sugar isomerase with the second sugar isomerization activity, the method including the steps of: 1) screening an enzyme essential for the first sugar metabolism through genomic analysis of the first sugar metabolic strain and a strain without the first sugar metabolic activity; 2) preparing a first sugar metabolic recombinant strain by introducing a gene encoding the enzyme screened in step 1) into a strain without the first sugar metabolic activity and the second sugar isomerization activity; 3) generating a second sugar isomerase mutant library by random mutagenesis; 4) introducing a gene mutant library obtained in step 3) into the first sugar metabolic recombinant strain prepared in step 2) to obtain a strain library; 5) culturing a strain of the library obtained in step 4) in a defined medium supplemented with the second sugar as a sole carbon source and screening the strain with faster growth rate; and 6) confirming a mutant enzyme introduced into the strain screened in step 5), in which the first sugar and the second sugar are mutual isomers.

Each step of the method can be performed according to the description of the method of rapidly screening the mutant with the second sugar isomerization activity and the first sugar metabolic activity as described above.

As disclosed in an embodiment of the present invention, the method of rapidly screening D-galactose isomerase mutants and L-arabinose isomerase mutants is characterized by being based on the cell growth-associated screening system.

The cell growth-associated screening system of the present invention means that a variety of candidate mutant genes are introduced into platform strains and that cell growth is confirmed, so that mutant genes showing activity based on this can be quickly selected and searched. More specifically, the present invention forms a L-arabinose isomerase mutant library, introduces them into a strain without D-galactose isomerization activity, strains are cultured in the defined medium containing D-galactose, and the growth of the strain is confirmed, thereby deriving particular mutant gene capable of effectively conferring D-galactose isomerization activity among a large number of mutant L-arabinose isomerase coding genes and using the same as D-galactose sugar isomerization mutant enzyme.

Further, the present invention provides a recombinant vector containing a gene encoding D-tagatose-1,6-bisphosphate aldolase and a gene encoding L-arabinose isomerase.

Further, the present invention provides a recombinant strain with D-galactose isomerization activity, in which the strain is introduced with a gene encoding D-tagatose-1,6-bisphosphate aldolase and a gene encoding L-arabinose isomerase.

The gene encoding the D-tagatose-1,6-bisphosphate aldolase may be a gene derived from a microorganism with tagatose metabolic activity, preferably a gatY gene (SEQ ID NO.: 5) derived from Bacillus licheniformis 14580. The amino acid sequence encoded thereby is represented by SEQ ID NO.: 7.

Further, the gene encoding L-arabinose isomerase of the present invention may be a gene derived from a microorganism with galactose metabolic activity, preferably an araA gene (SEQ ID NO.: 6) derived from Escherichia coli. The amino acid sequence encoded thereby is represented by SEQ ID NO.: 8.

The recombinant vector containing the gene encoding D-tagatose-1,6-bisphosphate aldolase and the gene encoding L-arabinose isomerase of the present invention is used to obtain the recombinant strain with D-galactose metabolic activity into which the gene encoding D-tagatose-1,6-bisphosphate aldolase and the gene encoding L-arabinose isomerase are introduced. The foreign gene is introduced to construct a newly modified sugar metabolic pathway in the recombinant strain. Thus, the recombinant strain may have new metabolic activity which may produce useful D-tagatose using a sugar, preferably D-galactose, which has not been conventionally available. A novel sugar metabolic pathway constructed according to the introduction of such a gene is shown in FIG. 1 as a schematic diagram.

As used herein, the terms “sugar isomerization” and “sugar conversion” can be used interchangeably.

As used herein, the term “vector” refers to a carrier for introducing a foreign gene into a strain and may be preferably a plasmid. The plasmid may be any of those commonly used in the art. However, in particular, the plasmid having the sequence map shown in FIG. 4 may be used to introduce the gatY gene, and the plasmid having the sequence map shown in FIG. 8 may be used to introduce the araA gene.

The recombinant strain of the present invention is a strain newly having D-galactose metabolic activity by introducing a gene encoding D-tagatose-1,6-bisphosphate aldolase and a gene encoding L-arabinose isomerase, as a foreign gene, and in particular, the recombinant strain is a strain into which a gene is introduced without D-galactose metabolic activity. The strain without D-galactose metabolic activity is not particularly limited in its kind but may belong to one species selected from the group consisting of Agrobacterium, Azospirillum Bacillus, Burkholderia, Clostridium, Enterobacter, Enterococcus, Escherichia, Flavobacterium, Klebsiella, Lactobacillus, Rhodobacter, Geobacillus, and Salmonella. Particularly, Escherichia coli belonging to Enterobacter, which is most commonly used for recombination, is most preferable.

The recombinant strain with D-galactose metabolic activity, into which a gene encoding D-tagatose-1,6-bisphosphate aldolase and a gene encoding L-arabinose isomerase are introduced, is a strain capable of converting D-galactose into D-tagatose and using tagatose for glycolysis, which is characterized as a strain having both D-galactose and D-tagatose metabolic activity and assimilation ability.

Further, the present invention provides a method of preparing a recombinant strain with D-galactose isornerization activity, the method including: introducing a gene encoding D-tagatose-1,6-bisphosphate aldolase and a gene encoding L-arabinose isomerase into a D-galactose non-metabolic strain.

In the present invention, the method for introducing the two kinds of genes into the host is not particularly limited, but is preferably a process of inserting the genes into a vector and using recombinant DNA technology such as electrophoresis and heat shock transformation method to introduce genes into the recombinant microorganism, resulting in co-expression in the recombinant strain. Specific examples of vectors that can be used are shown in FIGS. 4 and 8.

When a gene encoding D-tagatose-1,6-bisphosphate aldolase and a gene encoding L-arabinose isomerase are introduced into a strain, the introduction of the two genes may be carried out simultaneously or sequentially. There are no restrictions on the order of sequential use.

Further, the present invention provides a method of producing D-tagatose, the method including: culturing the recombinant strain with D-galactose metabolic activity, into which the gene encoding D-tagatose-1,6-bisphosphate aldolase and the gene encoding L-arabinose isomerase are introduced, in a medium supplemented with D-galactose.

According to the method, although a convention strain without D-galactose metabolic activity is used, D-galactose can be metabolized through the process of introducing the gene encoding D-tagatose-1,6-bisphosphate aldolase and the gene encoding L-arabinose isomerase. Thus, D-tagatose, which a useful substance, may be produced in a medium containing D-galactose as a substrate.

The D-galactose-containing medium may be a medium containing components compatible with the growth of the recombinant strain and may be a defined medium containing only D-galactose and/or glucose as a sole carbon source.

Further, the present invention provides an L-arabinose isomerase mutant enzyme with sugar isomerization activity, the enzyme being represented by one amino acid sequence selected from the group consisting of SEQ ID NO. 2 to SEQ ID NO. 4. The mutant enzyme is a mutant amino sequence of the sugar isomerization enzyme mutant screened by the cell growth-associated screening system. The mutant enzyme is an enzyme derived by random mutagenesis, then introducing the mutant into the strain, then culturing the recombinant strain in medium containing D-galactose, and then confirming the growth.

The L-arabinose isomerase mutant enzyme with the sugar isomerization activity of the present invention may include, without limitation, a sequence having 90% to 99%, preferably 95% to 97% and more preferably 97% to 99% of homologous to an enzyme represented by each of SEQ ID NOS: 2, 3 and 4 as long as having equivalents of the functions of sugar isomerase.

Hereinafter, the present invention is described in detail with reference to examples. However, the following examples are only illustrative of the present invention and are not intended to limit the scope of the present invention.

EXAMPLE 1: SCREENING OF PLATFORM HOST STRAIN LACKING THE D-GALACTOSE METABOLIC PATHWAY

The host strain lacking the D-galactose catabolic pathway was screened and confirmed by the following experiments. The genomic analysis of Escherichia coli BL21 (DE3) lacking the D-galactose utilization pathway was carried out. The results indicated that the strain lacks three chromosomal genes, galK (EC 2.7.1.6 galactosekinase), galT (EC 2.7.1.12 galactose 1-phosphate uridylyltransferase), and galE (EC 5.1.3.2 UDP-galactose 4-epimerase), encoding the enzymes involved in D-galactose metabolic pathway of the carbohydrate metabolism. Based on this information, culture experiments were performed to experimentally confirm the cell growth on the following strains: E. coli BL21 (DE3) lacking the D-galactose metabolism-related genes and E. coli DH5α with the D-galactose metabolism-related genes. They were cultured in a complex medium (LB) and a defined medium (M9) containing either 5 g/L glucose (glc) or 5 g/L D-galactose (gal) for 35 hours. The results are shown in FIG. 2.

As shown in FIG. 2, E. coli DH5α was able to use glucose and D-galactose as a carbon source, while E. coli BL21 (DE3) did not show the cell growth in a D-galactose-containing medium.

EXAMPLE 2: SEARCH FOR FOREIGN GENES ESSENTIAL FOR D-TAGATOSE METABOLISM

In order to search for enzymes and genes essential for D-tagatose catabolic pathway, the direct comparison and analysis were conducted on the genomic information of the microorganism Bacillus licheniformis 14580 with D-tagatose metabolic activity and the microorganism E. coli BL21 (DE3) without D-tagatose metabolic activity. The results are shown in FIG. 3.

As shown in FIG. 3, it was confirmed that the microorganism Bacillus licheniformis 14580 with D-tagatose metabolic activity had gatY genes encoding D-tagatose 1,6-bisphosphate aldolase in comparison with E. coli BL21 (DE3) without D-tagatose metabolic activity. Thus, they were selected as an essential enzyme for D-tagatose metabolism.

EXAMPLE 3: CONSTRUCTION OF A RECOMBINANT E. COLI STRAIN GROWING ON D-TAGATOSE
3.1 Construction of GatY Protein Expression Vector and E. Coli Transformants

An expression vector was constructed using the gatY gene expected to be essential for D-tagatose metabolism through Example 2 as described above. For the construction of the expression vector, the forward primer (Bli03552 gatY NdeI. F5-CATATGCTGACAAATACGAAAAAAATGC-3) and the reverse primer (Bli03552 gatY XhoI R 5-CTCGAGTTAGTATCTGTCATTGCTCATGC-3) containing the respective restriction enzyme sequences (NdeI or XhoI) were used for PCR in pairs in accordance with the manufacture of the expression vector. For the gene amplification, PCR was carried out using genomic DNA of Bacillus licheniformis cells as a template. In particular, the primeSTAR DNA polymerase by Takara corporation was used. 30 cycles having 98° C. for 30 secs, 57° C. for 5 secs and 72° C. for I min were carried out, followed by 72° C. for 10 mins. The amplified PCR product was electrophoresed and then separated and purified using a gel extract kit (Qiagen). After cloning using the pTOP blunt V2 cloning kit (Enzynomics), DNA sequencing (Solgent) was performed to confirm whether the respective gene mutation was introduced. After confirming the absence of mutation in genes obtained by FCR, in order to prepare gene expression vectors, the pET28(+) (Novagen) vector was treated with restriction enzymes (NdeI, XhoI), and in order to recover genes cloned into the pTOP Blunt V2 vector, the vector was treated with restriction enzymes corresponding to the expression vector. They were purified and separated using electrophoresis and gel extraction kit (Qiagen). The restriction enzyme-treated vector and the recovered genes were ligated using a DNA ligation kit (promega) to prepare an expression vector pET-28a(+)-BL_TBA. A gene map of the expression vector is shown in FIG. 4. Further, in order to prepare an E. coli transformant for gene expression, the expression vector shown in FIG. 4 was introduced into E. coli BL21 (DE3) in which D-galactose non-metabolic activity was confirmed. In order to selectively culture the transformant, the transformant was plated on an LB solid medium containing kanamycin, an antibiotic suitable for the antibiotic resistance gene contained in the above expression vector having a final concentration of 50 μg/ml and was cultured at 37° C. to form a single colony.

3.2 Identification of GatY Protein Expression in Escherichia Coli

The recombinant vector pET-28a(+)-BL_TBA obtained in 3.1 as described above was transformed into E. coli BL21 (DE3) strain. The cells were pre-cultured, and 1% of pre-cultured cells were added to LB supplemented with kanamycin (50 μg/ml) in a flask. The primary culture was performed. The expression of gatY gene was induced for 6 hours at 37° C. using IPTG (Isopropyl-D-1-thiogalactopyranoside) at a final concentration of 1 mM when the absorbance (600 nm) was 0.4-0.6.

The culture solution corresponding to 1 of the absorbance (600 nm) of cells inducing gatY protein expression was transferred to a 1.5 ml E-tube. After centrifugation, only the cultured cells were recovered. The cells were suspended in 100 μl of 1×SDS sample buffer. After treatment in boiling water for 10 minutes, 12% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) analysis was performed, and the results are shown in FIG. 5.

As shown in FIG. 5, it was confirmed that gatY protein (30 kDa) was expressed and that the gatY gene was introduced.

3.3 Characterization of the Growth Phenotypes of E. coli expressing TBA on D-Tagatose

In order to confirm whether or not E. coli BL21 (DE3) host cells obtain D-tagatose metabolic activity according to the recombinant gene expression, the transformed new E. coli host cell pET-28a(+)-BL_TBA/E. coli BL21 (DE3) obtained in 3.1 and 3.2 as described above, were cultured in a defined (M9) medium containing 5 g/L D-tagatose as a sole carbon source, and the cell growth was monitored by measuring the absorbance at 600 nm. The results are shown in FIGS. 6 and 7.

As shown in FIG. 6, the transformant with the foreign gene, gatY introduced even in the D-tagatose-containing medium, showed excellent growth and non-proliferation rate similar to that of the glucose-containing medium. As shown in FIG. 7, it was confirmed that E. coli BL21 (DE3) host cells overexpressing the gatY foreign gene encoding TBA, showed the smooth cell growth according to the foreign protein expression. However, it did not show the cell growth in the defined medium containing 0.5% D-galactose as the sole carbon source. Therefore, it was confirmed that additional sugar metabolic pathway modification is necessary to impart D-galactose metabolic activity.

EXAMPLE 4: PREPARATION OF AN AI-ACTIVITY-DEPENDENT, D-GALACTOSE UTILIZING STRAIN

AI was expressed in the host cell prepared in Example 3, that is, lacking D-galactose metabolic activity and having metabolic activity for D-tagatose, in order to develop a platform strain and screening system for searching for a sugar isomerase library.

For this example, the protein expression vector for AI was prepared. For the construction of the expression vector, first, the forward primer (ECAI NdeI F, 5′-CATATGACGATTTTTGATAATTATGAAGTGTGG-3′) and the reverse primer (ECAI HindIII R, 5′-AAGCTTTTAGCGACGAAACCCGTAATAC-3′) containing the respective restriction enzyme sequences (NdeI or HindIII) were prepared and used for the gene amplification. For the gene amplification using PCR, genomic DNA of E. coli cells was used as a template. The primeSTAR HS DNA polymerase by Takara corporation was used. 30 cycles having 98° C. for 30 secs, 57° C. for 5 secs and 72° C. for 1 min and 40 secs were carried out, followed by 72° C. for 10 mins. The amplified PCR product was electrophoresed and then separated and purified using a gel extract kit (Qiagen). After cloning using the pTOP blunt V2 cloning kit (Enzynomics), DNA sequencing (Solgent) was performed to confirm whether the respective gene mutation was introduced. After confirming the absence of mutation in genes obtained by PCR, in order to prepare gene expression vectors, the pET-22b(+) (Novagen) vector was treated with restriction enzymes (NdeI, HindIII), and in order to recover genes cloned into the plOP Blunt V2 vector, the vector was treated with restriction enzymes corresponding to the expression vector. They were purified and separated using electrophoresis and gel extraction kit (Qiagen). The restriction enzyme-treated vector and the recovered genes were ligated using a DNA ligation kit (promega) to prepare an expression vector pET-22b(+)-ECAI. A gene map of the expression vector prepared is shown in FIG. 8.

E. coli transformants were prepared as follows for the gene expression. The recombinant expression vector shown in FIG. 8 was introduced into E. coli pET-28a(+)-BL_TBA/BL21 (DE3) strain with D-tagatose metabolic activity, in which D-galactose non-metabolic activity was confirmed. In order to selectively culture the transformant, the transformant was plated on an LB solid medium containing ampicillin, an antibiotic suitable for the antibiotic resistance gene contained in the above expression vector having a final concentration of 100 μg/ml and was cultured at 37° C. to form a single colony. After the cells were pre-cultured, 1% of pre-cultured cells were added to LB supplemented with ampicillin (100 μg/ml) in a flask. The primary culture was performed. The cells were mainly cultured. The expression of araA gene was induced for 6 hours at 37° C. using IPTG (Isopropyl-D-1-thiogalactopyranoside) at a final concentration of 1 mM when the absorbance (600 nm) was 0.4-0.6. The culture solution corresponding to 1 of the absorbance (600 nm) of cells inducing protein expression was transferred to a 1.5 ml E-tube. After centrifugation, only the cultured cells were recovered. The cells were suspended in 100 μl of 1× SDS sample buffer. After treatment in boiling water for 10 minutes, 12% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) analysis was performed to confirm the expression of the gatY gene (31 kDa) encoding the D-tagatose 1, 6-bisphosphate aldolase enzyme and the expression of the araA gene (56 kDa) encoding the L-arabinose isomerase in E. coli as shown in FIG. 9.

As shown in FIG. 9, the gatY gene (31 kDa) encoding the D-tagatose 1, 6-bisphosphate aldolase enzyme and the araA gene (56 kDa) encoding the L-arabinose isomerase were expressed in the transformed E. coli.

In order to assay the activity and cell growth of isomerase of the prepared cell growth-associated screening system, E. coli BL21 (DE3) in which pET-22b(+)-ECAI and pET-28(+)-gatY were transformed was cultured in a defined (M9) medium containing the antibiotics ampicillin (50 μg/ml) and kanamycin (25 μg/ml) suitable for the two plasmids, 0.05 g/L fructose, 0.45 g/L D-galactose and IPTG with a final concentration of 0.2 mM to confirm the cell growth curve of D-galactose isomerization activity of sugar isomerase. The results are shown in FIG. 10.

As shown in FIG. 10, it was confirmed that the strain in which the gatY gene encoding the D-tagatose 1, 6-bisphosphate aldolase enzyme and the araA gene encoding the L-arabinose isomerase were added in E. coli BL21 (DE3) strain which did not grow in the medium containing D-galactose showed the cell growth, and that D-galactose can be used as the sole carbon source due to the activity of the isomerase.

EXAMPLE 5: SCREENING OF SUGAR ISOMERIZING ACTIVITY WITH THE PROTO-TYPE SUGAR ISOMERASE AND ITS VARIANTS
5.1 Generation of the araA Mutants

In order to generate the araA gene mutants, mutagenic PCR was performed with a PCR random mutagenesis kit (Clontech, USA). 50 ng of the error-prone PCR library DNA was transformed into E. coli BL21 (DE3) containing plasmid pET-28a(+)-BL_TBA, and the cells were cultured in the defined (M9) medium containing 0.05 g/L fructose and 0.45% D-galactose. Thereafter, the formed colonies were collected, and the plasmid was extracted using a plasmid purification kit. 8 kinds of these plasmids were sequenced and their genetic diversity of the library was confirmed.

5.2 Screening of Sugar Isomerase Variants using a Cell Growth-Associated Screening System

Recombinant E. coli BL21 (DE3) harboring pET-28a(+)-BL_TBA were transformed with araA genetic libraries (i.e., pET-22b(+)-ECAI_Var). Transformants harboring pET-28a(+)-BL_TBA and pET-22b(+)-ECAI_Var were grown in the defined medium (M9) containing 0.05 g/L fructose and 0.45 g/L D-galactose as a carbon source and IPTG with a final concentration of 0.2 mM, and the cell growth was confirmed. The results are shown in FIG. 11.

As shown in FIG. 11, it was confirmed that as the protein expression of the mutant gene library was varied, the level of the cell growth and the non-proliferation rate were different. These indicate that the ability to utilize D-galactose as a carbon source may vary depending on the introduction of the araA gene and its mutation.

5.3. Verification of D-galactose availability of Sugar Isomerase Variants

The plasmids were isolated from the sugar isomerase variants and the wild type selected by the cell growth-associated screening system of 5.2 above as follows: pET-22b(+)-ECAI H17R/R159S/V168A, pET-22b(+)-ECAI E22 D/M95L/H157L, and pET-22b(+)-ECAI-V368A/E493D. Further, the sequencing of the isolated plasmids was performed to analyze the mutant amino acid sequences of the mutants selected by the cell growth-associated screening system. They are represented by SEQ ID NOS.: 2 to 4, respectively. The amino acid sequence of the wild-type ECAI is represented by SEQ ID NO.: 1.

In addition, Ni2+ column chromatography was performed to purely isolate the mutant enzymes, and the activity of the mutant enzymes was compared with the ECAI wild type enzyme. That is, the activity of host strain, ECAI wild-type and sugar isomerization enzyme variants on D-galactose was measured and compared, and the results are shown in FIG. 12.

As shown in FIG. 12, it was confirmed that pET-22B(+)-ECAI H17R/R159S/V168A-derived mutant enzyme (SEQ ID NO.: 2), pET-22b(+)-ECAI E22D/M95L/H157L-derived mutant enzyme (SEQ ID NO.: 3), and pET-22b(+)-ECAI-V368A/E493D-derived mutant enzyme (SEQ ID NO.: 4) increased the activity to D-galactose up to 80%.

These results indicate that when a mutant library of L-arabinose isomerase (AI) by random mutagenesis was generated, then the library was introduced into a strain and form strain library. And then D-galactose metabolic activity was assayed through cell growth, specific mutagenic enzymes and sugar isomerase, L-arabinose isomerase variants that can impart D-galactose metabolic activity can be rapidly selected.

Although the present invention has been described in terms of the preferred embodiments as described above, it is possible to make various modifications and variations without departing from the spirit and scope of the present invention. It is also to be understood that the appended claims are intended to cover such modifications and variations falling within the scope of the present invention.

Number	Date	Country	Kind
10-2016-0178419	Dec 2016	KR	national
10-2017-0044740	Apr 2017	KR	national

A RECOMBINANT STRAIN HAVING MODIFIED SUGAR METABOLIC PATHWAY AND METHOD FOR SCREENING SUGAR ISOMERASE USING SAME

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

Priority Claims (2)

PCT Information